Clinical Trial

Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 20, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Leptomeningeal metastasis, characterized by tumor cells infiltrating and proliferating in the subarachnoid space, represents a distinct pattern of central nervous system involvement and is a fatal complication of malignant tumors. This phase I/II study is to evaluate the recommended dose, safety, feasibility, and therapeutic response of intrathecal PD-1/VEGF bispecific antibody plus pemetrexed in patients with leptomeningeal metastasis.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-01; most recent amendment 2025-05-15.
Status change: Not Yet Recruiting → Recruiting 2025-03-20
Trial Details
NCT Number NCT06809517
Lead Sponsor Guangzhou Medical University
Conditions Leptomeningeal Metastasis, Intrathecal Drug Delivery
Enrollment 34 participants
Start Date 2025-03-18
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-05-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-20